TITLE

Potential Interaction between Clopidogrel and Proton Pump Inhibitors

AUTHOR(S)
Howard, Patricia A.; Vacek, James L.
PUB. DATE
December 2009
SOURCE
American Journal of Cardiovascular Drugs;2009, Vol. 9 Issue 6, p353
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Clopidogrel is widely used in patients with acute coronary syndromes and following percutaneous coronary intervention with stent implantation. The antiplatelet action of clopidogrel is felt to be of critical importance for the reduction of abrupt thrombotic occlusion of stents, particularly with drug-eluting devices. When clopidogrel is used alone or in combination with aspirin (acetylsalicylic acid), the benefits of antiplatelet therapy must be weighed against the potential for serious bleeding, particularly gastrointestinal (GI) bleeds. To minimize the risk of GI injury, proton pump inhibitors (PPIs) are considered the drugs of choice. However, a growing body of evidence suggests that PPIs may adversely interact with clopidogrel, diminishing the antiplatelet effect. Although the current evidence remains controversial, the potential for increased risk of thrombotic complications warrants cautious use of this drug combination until further research can determine the extent of this interaction and whether it is a drug-class effect.
ACCESSION #
48122983

 

Related Articles

  • Antiplatelet therapy for secondary prevention of coronary artery disease. Pilgrim, Thomas; Windecker, Stephan // Heart;Nov2014, Vol. 100 Issue 22, p1750 

    The choice and duration of antiplatelet therapy for secondary prevention of coronary artery disease (CAD) is determined by the clinical context and treatment strategy. Oral antiplatelet agents for secondary prevention include the cyclo-oxygenase-1 inhibitor aspirin, and the ADP dependent P2Y12...

  • Clopidogrel and aspirin.  // Primary Care Reports;Jun2010 Pharmacology, p2 

    The article discusses a study on the efficacy of antiplatelet therapy with clopdigrel and aspiring in patients with drug-eluting stents.

  • Proton Pump Inhibitors and the Prevention of Recurrent GI Bleed in Patients Treated with Clopidogrel. Oyetayo, O.O.; Farris, C.A.; Wahawisan, J. // Clinical Medicine Insights: Therapeutics;2012, Issue 4, p9 

    Clopidogrel is an antiplatelet agent indicated in the management of atherothrombotic conditions. Bleeding is a predictable adverse event associated with antiplatelet agents. While non-ulcerogenic; a major site of bleeding with clopidogrel is the gastrointestinal (GI) tract. The risk of GI...

  • High Maintenance Dosage of Clopidogrel is Associated with a Reduced Risk of Stent Thrombosis in Clopidogrel-Resistant Patients. Tavassoli, Neda; Voisin, Sophie; Carrie, Didier; Lapeyre-Mestre, Maryse; Galinier, Michel; Montastruc, Jean Louis; Pathak, Atul // American Journal of Cardiovascular Drugs;2010, Vol. 10 Issue 1, p29 

    Background: Stent thrombosis remains an important complication after stent implantation, despite the use of dual antiplatelet therapy with aspirin (acetylsalicylic acid) and clopidogrel. Several studies have shown an increased risk of thrombotic events in patients with resistance to clopidogrel....

  • Ticagrelor: a guide to its use in the management of acute coronary syndromes. Scott, Lesley J.; Deeks, Emma D. // Drugs & Therapy Perspectives;Jan2012, Vol. 28 Issue 1, p1 

    The article reports on the pharmacokinetics and tolerability profile of the drug ticagrelor, an oral antiplatelet agent which is used for the prevention of atherothrombotic events in adults with acute coronary syndromes. A discussion of research which investigated the efficacy of ticagrelor is...

  • Ticagrelor: An oral, non-thienopyridine P2Y12 receptor antagonist for the treatment of acute coronary syndromes. Jennings, Douglas L. // Formulary;May2010, Vol. 45 Issue 5, p148 

    Coronary heart disease and acute coronary syndromes (ACS) are a significant cause of morbidity and mortality in the United States. The cornerstone of ACS management is combination oral antiplatelet therapy, usually with aspirin and a thienopyridine. Clopidogrel, the most commonly used...

  • Optimal Duration of Clopidogrel Use after Implantation of Drug-Eluting Stents � Still in Doubt. Berger, Peter B. // New England Journal of Medicine;4/15/2010, Vol. 362 Issue 15, p1441 

    The author reflects on whether stent thrombosis is a result of the use of drug-eluting stents and the required duration of dual antiplatelet therapy after implantation of drug-eluting stents. He explains the relationship between stent thrombosis and large myocardial infarction or death. The...

  • Duration of dual antiplatelet therapy following percutaneous coronary intervention on rehospitalization for acute coronary syndrome. Shih-Chin Chen; Fei-Yuan Hsiao; Chii-Ming Lee; William Wei-Yuan Hsu; Churn-Shiouh Gau // BMC Cardiovascular Disorders;2014, Vol. 14 Issue 1, p1 

    Background The optimal duration of dual antiplatelet therapy after percutaneous coronary intervention (PCI) remains uncertain. The objective of this study was to examine the association between duration of dual antiplatelet therapy and re-hospitalization for acute coronary syndrome (ACS) in ACS...

  • Antiplatelet therapy for secondary prevention of coronary artery disease. Pilgrim, Thomas; Windecker, Stephan // Postgraduate Medical Journal;May2015, Vol. 91 Issue 1075, p284 

    The choice and duration of antiplatelet therapy for secondary prevention of coronary artery disease (CAD) is determined by the clinical context and treatment strategy. Oral antiplatelet agents for secondary prevention include the cyclo-oxygenase-1 inhibitor aspirin, and the ADP dependent P2Y12...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics